The Use of Granulin-Epithelin Precursor (GEP) Anitbodies for Detection and Suppression of Hepatocellular Carcinoma (HCC)
This invention provides methods for detecting serum GEP level. This invention further provides methods for determining whether a subject is afflicted with Hepatocellular carcinoma (HCC) by measuring serum GEP level. In another embodiment, this invention provides methods for the suppression of HCC growth and progression both in vitro and in vivo by treating a patient with anti-GEP monoclonal antibody A23.
Patent Number: US20080199470A1
Application Number: US2007946260A
Inventor: Cheung, Siu Tim | Ho, Chung Yee Jenny | Fan, Sheung Tat
Priority Date: 29 Apr 2004
Priority Number: US20080199470A1
Application Date: 28 Nov 2007
Publication Date: 21 Aug 2008
IPC Current: A61K0039395 | A61P000100 | G01N003353 | G01N0033566 | G01N0033574
US Class: 4241381 | 43500723 | 43500792 | 436501
Title: The Use of Granulin-Epithelin Precursor (GEP) Anitbodies for Detection and Suppression of Hepatocellular Carcinoma (HCC)
Usefulness: The Use of Granulin-Epithelin Precursor (GEP) Anitbodies for Detection and Suppression of Hepatocellular Carcinoma (HCC)
Summary: The methods are useful for detecting GEP protein in a biological sample; determining whether a subject has HCC; and suppressing HCC cell proliferation or growth in a mammalian patient (all claimed).
Novelty: Detecting Granulin-Epithelin Precursor (GEP) protein in a biological sample by incubating the sample with anti-GEP monoclonal antibody, anti-GEP polyclonal antibody, horseradish peroxidase-conjugated anti-rabbit immunoglobulin G
诊断/治疗
癌症/肿瘤
香港
